ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report

ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report

BackgroundCases of ALK-rearranged EGFR wild-type lung adenocarcinoma (LUAD) transforming into small cell lung cancer (SCLC) are rarely reported, and diagnosis is often delayed. The emergence of this transformation phenomenon is often regarded as a consequence of acquired resistance mechanisms.Case p...

Full description

Bibliographic Details
Main Authors:	Rui Chen, Yan Jian, Yuzhen Liu, Junping Xie
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Oncology
Subjects:	non-small cell lung cancer small cell lung cancer transformation ALK-TKIs liver metastasis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1395654/full

Similar Items

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
by: Tomasz Marjanski, et al.
Published: (2021-11-01)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
by: Zhe-Rong Zheng, et al.
Published: (2023-03-01)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01)

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
by: K. K. Laktionov, et al.
Published: (2019-06-01)

High efficacy of brigatinib for brain metastases in ALK fusion gene‐positive non‐small cell lung cancer: A case series
by: Kei Morikawa, et al.
Published: (2024-02-01)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
by: Valerio Gristina, et al.
Published: (2020-12-01)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
by: Peng Song, et al.
Published: (2019-04-01)

An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report
by: Gabriela Chowaniecova, et al.
Published: (2022-12-01)

Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports
by: Lionel Michaux, et al.
Published: (2023-06-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
by: Ming-Hung Huang, PhD, et al.
Published: (2022-11-01)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
by: Tzu-Hsuan Chiu, et al.
Published: (2021-09-01)

Diverse Resistant Mechanisms Identified Using Serial Next-Generation Sequencing in a Patient With ALK-Rearranged Metastatic Lung Adenocarcinoma: A Case Report
by: Stephanie Pei Li Saw, MRCP, et al.
Published: (2023-06-01)

Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study
by: Jing Qian, et al.
Published: (2024-01-01)

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors
by: Jianxin Chen, et al.
Published: (2023-07-01)

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
by: Andreas Koulouris, et al.
Published: (2022-07-01)

ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
by: Georgios Tsakonas, et al.
Published: (2020-07-01)

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC
by: Federica Zito Marino, et al.
Published: (2020-07-01)

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives
by: Valeria Cognigni, et al.
Published: (2022-09-01)

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review
by: Anna Rekowska, et al.
Published: (2022-05-01)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
by: Kazushige Wakuda, et al.
Published: (2023-09-01)

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer
by: Zizong Wang, et al.
Published: (2023-05-01)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
by: Bei Zheng, et al.
Published: (2023-08-01)

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma
by: Thomas Pasau, et al.
Published: (2022-11-01)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
by: Rohit Thummalapalli, MD, et al.
Published: (2023-08-01)

Immunotherapy for <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
by: Kamya Sankar, et al.
Published: (2021-03-01)

Novel Dual-Target Kinase Inhibitors of EGFR and ALK Were Designed, Synthesized, and Induced Cell Apoptosis in Non-Small Cell Lung Cancer
by: Yangyang Fan, et al.
Published: (2023-02-01)

Incidence and patterns of <it>ALK</it> FISH abnormalities seen in a large unselected series of lung carcinomas
by: Dai Zunyan, et al.
Published: (2012-12-01)

Current approaches to therapy of ALK-positive non-small cell lung cancer
by: К. К. Laktionov, et al.
Published: (2021-06-01)

Correlation between ALK, ROS1 Biomarkers and EGFR Oncogene Mutations in Lung Tumours: Our Observations in an Apex Oncopathology Laboratory
by: Raja Ratna Kishore, et al.
Published: (2023-05-01)

Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case
by: A. V. Sultanbaev, et al.
Published: (2020-12-01)

Lung adenocarcinoma relapse with emerging EGFR mutation following complete response of small cell lung cancer warrants routine re-biopsy: A case report
by: Minna Zhang, et al.
Published: (2022-10-01)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
by: Tung Hoang, et al.
Published: (2020-02-01)

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain
by: Margarita Majem, et al.
Published: (2022-09-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
by: Iso H, et al.
Published: (2023-06-01)

Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview
by: Delphine Antoni, et al.
Published: (2021-05-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

A case of ALK-rearranged lung adenocarcinoma associated with syndrome of inappropriate antidiuretic hormone
by: Yoshihiro Miyashita, et al.
Published: (2020-01-01)

Anti-Angiogenic Therapy in <i>ALK</i> Rearranged Non-Small Cell Lung Cancer (NSCLC)
by: Aaron C. Tan, et al.
Published: (2022-08-01)